Immunovant Inc (IMVT) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and...

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 4 - Statement of changes in beneficial ownership of securities

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 24, 2025 NEW...

Form D - Notice of Exempt Offering of Securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Immunovant Announces $450 Million Private Placement

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology...

Form 4 - Statement of changes in beneficial ownership of securities